Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Creative Medical Technology Holdings (CELZ) EBITDA Margin (2017 - 2025)

Creative Medical Technology Holdings (CELZ) has disclosed EBITDA Margin for 10 consecutive years, with 55349.27% as the latest value for Q1 2025.

  • On a quarterly basis, EBITDA Margin changed N/A to 55349.27% in Q1 2025 year-over-year; TTM through Sep 2025 was 101379.43%, a 5019792.0% decrease, with the full-year FY2024 number at 52216.92%, up 1022899.0% from a year prior.
  • EBITDA Margin was 55349.27% for Q1 2025 at Creative Medical Technology Holdings, up from 62857.8% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1855.31% in Q3 2022 to a low of 62857.8% in Q4 2024.
  • A 5-year average of 25661.6% and a median of 20316.32% in 2024 define the central range for EBITDA Margin.
  • Biggest YoY gain for EBITDA Margin was 647905bps in 2022; the steepest drop was -3157871bps in 2022.
  • Creative Medical Technology Holdings' EBITDA Margin stood at 2173.64% in 2021, then tumbled by -1453bps to 33752.35% in 2022, then plummeted by -75bps to 59061.3% in 2023, then fell by -6bps to 62857.8% in 2024, then rose by 12bps to 55349.27% in 2025.
  • Per Business Quant, the three most recent readings for CELZ's EBITDA Margin are 55349.27% (Q1 2025), 62857.8% (Q4 2024), and 20316.32% (Q2 2024).